Medicare proposes coverage limits for anti-anemia drugs

Medicare has proposed new restrictions on what it will cover for cancer patients prescribed anti-anemia drugs known as erythropoiesis-stimulating agents because of ties to death risks. Amgen makes Aranesp and Epogen and Johnson & Johnson makes Procrit for treating the problem, and they are expected to suffer the hardest hit if the Medicare proposal becomes final.

View Full Article in:

CNNMoney · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA